Skip to main content
PharmaBlock Sciences (Nanjing), Inc. logo

PharmaBlock Sciences (Nanjing), Inc. — Investor Relations & Filings

Ticker · 300725 ISIN · CNE1000035K5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,618 across all filing types
Latest filing 2023-08-14 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300725

About PharmaBlock Sciences (Nanjing), Inc.

https://www.pharmablock.com

PharmaBlock Sciences (Nanjing), Inc. specializes in the design and manufacture of innovative building blocks and provides integrated chemistry services for drug discovery and development. The company offers a comprehensive portfolio of structurally diverse scaffolds and intermediates used to enhance the efficiency of medicinal chemistry. Its core capabilities include process research and development, scale-up production, and commercial-scale manufacturing under CDMO frameworks. By utilizing advanced chemical technologies and a vast library of unique chemical entities, the company supports global biotechnology and pharmaceutical organizations in streamlining their research pipelines and optimizing the transition from discovery to clinical development and commercialization.

Recent filings

Filing Released Lang Actions
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Nanjing Yaoshi Technology Co., Ltd. It details the approval of the company's 2023 semi-annual report and related matters, including the use of raised funds and related party transactions. The document does not contain the actual semi-annual report or financial statements but refers readers to the full report published on an external website. The document length is short (1444 characters) and serves as an official announcement of meeting resolutions rather than the report itself. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA) or similar announcement type, but since it is a formal resolution announcement of the Supervisory Board meeting, it fits best under Regulatory Filings (RNS) as it does not contain the full report or detailed financial data itself.
2023-08-14 Chinese
2023年上半年非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 85% confidence The document is a detailed tabular summary of non-operating fund occupation and other related party fund transactions for the first half of 2023. It includes specific financial figures, accounting subjects, and relationships with related parties. The content is financial and operational in nature but does not represent a full annual or interim report. It is a specific financial summary related to related party transactions and fund usage, which is typically part of management or financial disclosures but not a full report like an Annual Report (10-K) or Interim Report (IR). The document length is 4595 characters, which is relatively short and focused on a specific financial topic. It is not an announcement or a certification but a financial summary table. Given the specificity and financial detail, the best fitting category is Regulatory Filings (RNS) as it is a regulatory disclosure of related party transactions and fund usage that does not fit other more specific categories.
2023-08-14 Chinese
华泰联合证券有限责任公司关于南京药石科技股份有限公司2023年上半年度持续督导跟踪报告
Regulatory Filings Classification · 95% confidence The document is titled as a '2023年上半年度持续督导跟踪报告' (2023 First Half Year Continuous Supervision Follow-up Report) issued by the sponsoring institution 华泰联合证券有限责任公司 regarding 南京药石科技股份有限公司. It references regulatory frameworks related to securities law and Shenzhen Stock Exchange rules, and details the sponsor's ongoing supervision activities, including information disclosure review, governance, fundraising supervision, and other compliance matters for the first half of 2023. The document contains no financial statements or detailed financial data but is a regulatory compliance and supervision report by the sponsor. It is not an annual or interim financial report, nor an earnings release or audit report. It is a specific type of regulatory supervision report related to continuous sponsor oversight. Given the content and nature, it fits best under Regulatory Filings (RNS) as a general regulatory compliance document that does not fit other specific categories.
2023-08-14 Chinese
2023年半年度募集资金存放与使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2023 Half-Year Special Report on the Deposit and Use of Raised Funds" by Nanjing Yaoshi Technology Co., Ltd. It details the use and management of funds raised through stock issuance and convertible bonds, including amounts raised, usage, balances, and regulatory compliance. The document references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and includes detailed tables on fund usage and changes in investment projects. The content is focused on the specific use and management of raised capital, not a general financial report or earnings release. It is a specialized report on fundraising and capital usage, matching the description of a Capital/Financing Update (CAP). The document length is over 12,000 characters, indicating it is a full report, not just an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2023-08-14 Chinese
华泰联合证券有限责任公司关于南京药石科技股份有限公司2023年度日常关联交易额度预计的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from Huatai United Securities Co., Ltd. regarding the expected daily related-party transaction limits for Nanjing Yaoshi Technology Co., Ltd. for the year 2023. It includes detailed descriptions of related-party transactions, amounts, related parties, pricing principles, and independent directors' opinions. The document is a formal verification and opinion report by the sponsor institution on the company's expected related-party transactions for the year, which is a regulatory compliance and audit-related document rather than a full annual or interim financial report. It does not contain comprehensive financial statements or management discussion and analysis but focuses on audit and verification of related-party transactions. Therefore, it fits best under the category of Audit Report / Information (AR). The document length (8046 characters) and content confirm it is a substantive report, not a brief announcement or certification letter, so it is not RPA or RNS.
2023-08-14 Chinese
2023年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2023 Half-Year Report Summary' (半年度报告摘要) for the company 南京药石科技股份有限公司. It contains financial data for the half-year period, including revenue, net profit, earnings per share, assets, liabilities, shareholder information, and bond details. The document explicitly states it is a summary of the half-year report and advises investors to read the full half-year report for comprehensive information. The length is about 2961 characters, which is relatively short and consistent with a summary rather than a full report. The content includes substantive financial data and analysis for a period shorter than a full fiscal year, which fits the definition of an Interim / Quarterly Report (IR). It is not an announcement of a report publication, nor a certification or a brief factsheet. Therefore, the correct classification is Interim / Quarterly Report (IR).
2023-08-14 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.